SAB Biotherapeutics Inc., a clinical-stage biopharmaceutical company, has filed a prospectus announcing an oversubscribed private placement, raising $175 million in gross proceeds. The financing includes participation from strategic investor Sanofi, alongside new investors such as RA Capital Management and Blackstone Multi-Asset Investing, among others. The funds are earmarked to fully support the pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly diagnosed patients. The company expects this infusion to extend its cash runway into mid-2028. Additionally, there is potential for up to $284 million in extra gross proceeds if milestone-based warrants are fully exercised. The placement is scheduled to close around July 22, 2025, subject to customary conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.